Medical/Pharmaceuticals
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has be...
2025-08-15 09:35
2096
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future
BOSTON, Aug. 14, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with itsOrchestration Platfor...
2025-08-14 22:00
1883
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LB...
2025-08-14 17:38
2172
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...
2025-08-14 12:02
2099
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
* Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irr...
2025-08-14 08:00
1931
The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer's Association, and CurePSP Join Forces to Award $2.5 Million in Neurodegenerative Disease Research Grants from 2025 Tauopathy Challenge Workshop
Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs). FORT WORTH, Texas, Aug. 13, 2...
2025-08-13 20:00
1975
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in...
2025-08-13 19:30
1549
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndr...
2025-08-13 17:57
1792
Avive Health to host Queensland's first Empax clinic in landmark mental health partnership with Emyria
BRISBANE, Australia, Aug. 13, 2025 /PRNewswire/ -- Avive Health ("Avive"), an Australian-owned private mental health provider, has announced a major national partnership with Emyria Limited (ASX: EMD), marking a significant milestone in the evolution of evidence-based, reimbursable mental heal...
2025-08-13 15:40
2196
Prince Court Medical Centre Strengthens Malaysia's Position as a Global Healthcare Destination with First Kelly Procedure
KUALA LUMPUR, Malaysia, Aug. 13, 2025 /PRNewswire/ -- Prince Court Medical
Centre has placedMalaysia firmly on the global medical tourism map by
successfully performing the country's first Kelly procedure, an advanced
reconstructive surgery for rare congenital urological conditions.
2025-08-13 15:16
2003
KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration
SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company ") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr....
2025-08-13 09:44
4475
Manipal Hospitals Kolkata completes 50 successful TAVR cases
KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital),Kolkata is thrilled to announce the completion of50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in struc...
2025-08-12 17:29
1493
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...
2025-08-12 17:00
1965
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based...
2025-08-11 21:41
2691
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions
HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global
provider of GxP-compliant digital solutions for the life sciences industry,
proudly announces the start of its 25th year of operations.
2025-08-11 21:22
2848
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK
Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conferenc...
2025-08-11 20:06
1574
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...
2025-08-11 17:11
1885
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. * WuXia293Stable platform maintains stable expression and consistent product quality during long-term c...
2025-08-11 16:30
1849
Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino
MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entr...
2025-08-11 10:31
1976
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment
SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch ofFibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], ...
2025-08-11 09:00
1581
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 309 media titles]
2026-01-15 13:00Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 299 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 280 media titles]
2026-01-16 11:00
Docquity Launches Engage™, an AI and Insights-Powered HCP Intelligence Engine for the Life Sciences Industry
[Picked up by 278 media titles]
2026-01-15 13:00Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
5881
